Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Dec;21(4):667-75.
doi: 10.1016/j.beha.2008.06.005.

What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?

Frederick R Appelbaum  1
Affiliations
Review

What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?

Frederick R Appelbaum. Best Pract Res Clin Haematol. 2008 Dec.

Abstract

Acute myeloid leukemia (AML) patients over the age of 55 years are generally more difficult to treat than younger patients due to intrinsic drug resistance and diminished tolerance to treatment. The unfortunate result is that conventional chemotherapy is toxic and rarely curative. Recent studies suggest a better outcome for older AML patients treated with reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) than those treated with conventional chemotherapy. However, there are major limitations to RIC HCT. Some of these limitations may be able to be overcome, broadening the impact of allogeneic RIC HCT for older patients with AML. Ways to improve RIC HCT include making more patients eligible for RIC HCT by improving initial complete response rates using novel agents or combinations; finding a way to more rapidly identify alternative stem cell sources, such as by using donors that have already undergone HLA profiling or by using unrelated cord blood; eliminating the requirement for a complete response prior to transplant; and educating patients and physicians about the chances of survival after RIC HCT when compared to conventional chemotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival among 348 patients aged older than 55 years with previously untreated AML entered onto a recent ECOG trial.
Figure 2
Figure 2
Survival of 122 patients with AML in CR1, CR2, or with more advanced disease treated with reduced-intensity conditioning using the Seattle regimen.
Figure 3
Figure 3
Relapse-free survival among 97 patients with AML or high-risk myelodysplastic syndrome who achieved CR1, including those who did not have a consult for possible transplant, those who had a consult but no donor, those who had a donor but didn't receive a transplant, and those who received a transplant.
See this image and copyright information in PMC

References

    1. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485. - PMC - PubMed
    1. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89:3323–3329. - PubMed
    1. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312–1320. - PubMed
    1. Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006;108:3280–3288. - PubMed
    1. van der HB, Breems DA, Berna BH, et al. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. Br J Haematol. 2007;136:96–105. - PubMed